Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, May 14, 2025, to discuss the Company's third quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information: Third Quarter 2025 Earnings Conference Call Date: Thursday, August 14, 2025 Time: 8:30 a.m. Eastern time U.S. Dial-In (Toll Free): 888-506-0062 International Dial-In: 973-528-0011 Participan ...

Core Insights - NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF Ablation System, has surpassed one year seizure-free, significantly improving her quality of life [1][2] - The OneRF Ablation System is the first FDA 510(k)-cleared device that utilizes the same sEEG electrode for both diagnostic and therapeutic applications, demonstrating seizure reduction or freedom for most patients treated [3] - The company plans to leverage the OneRF technology for additional applications, including the OneRF Trigeminal Nerve Ablation System for facial pain, with a 510(k) submission filed in April 2025 [4] Company Overview - NeuroOne Medical Technologies Corporation focuses on developing minimally invasive and high-definition solutions for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain, aiming to improve patient outcomes and reduce procedural costs [5] - The company is exploring potential applications in other areas such as depression, mood disorders, and artificial intelligence [5]